

Original Article

Discussing the advancements in kidney transplantation, including donor selection, immunosuppression, and long-term outcomes for recipients

¹ Ali Raza, ²Fazal Mehmood, ³Nadia Niaz, ⁴Mobeen Ali, ⁵Kamran Safdar

¹PIMS

²Baluchistan Institute of Nephro Urology
Quetta

³Balochistan Institute of Nephro Urology
Quetta

⁴PIMS

⁵PIMS

Correspondence
Ali Raz, PIMS

Abstract

Background: Kidney transplantation has evolved significantly over the past few decades, driven by advancements in donor selection, immunosuppression strategies, and long-term recipient management. These developments have contributed to improved outcomes, reduced complications, and extended graft survival, addressing the critical need for effective treatment in end-stage renal disease patients.

Aim: This study aimed to evaluate the impact of recent advancements in kidney transplantation on donor selection criteria, immunosuppressive regimens, and the long-term outcomes for transplant recipients.

Methods: A retrospective analysis was conducted from June 2023 to May 2024, involving a study population of 90 kidney transplant recipients. Data were collected on donor selection processes, immunosuppressive therapies used, and long-term outcomes, including graft survival and recipient health. The study assessed the correlation between these variables and patient outcomes using statistical methods.

Results: The study found that advancements in donor selection, particularly the use of expanded criteria donors, significantly increased the donor pool without compromising graft survival. Innovations in immunosuppression, including the use of newer agents and personalized regimens, were associated with a decrease in acute rejection rates and long-term complications. Overall, the long-term outcomes for recipients showed marked improvement, with a higher percentage of patients achieving sustained graft function and improved quality of life.

Conclusion: The advancements in kidney transplantation have led to significant improvements in both short-term and long-term outcomes for recipients. Enhanced donor selection criteria and modern immunosuppressive therapies have expanded the availability of organs and reduced the incidence of graft rejection, ultimately contributing to better patient survival and quality of life.

Keywords: Kidney transplantation, donor selection, immunosuppression, graft survival, long-term outcomes, end-stage renal disease.

INTRODUCTION:

Kidney transplantation has long been recognized as the optimal treatment for patients with end-stage renal disease (ESRD), offering significantly improved quality of life and survival compared to dialysis. Over the past few decades, substantial advancements have been made in the field of kidney transplantation, particularly in the areas of donor selection, immunosuppression, and the long-term outcomes for recipients [1]. These developments have collectively contributed to the enhancement of graft survival rates and have positively impacted the lives of thousands of patients worldwide.

In the past, donor selection for kidney transplantation primarily relied on deceased donors, with living donors being a less common option due to the associated risks and ethical considerations [2]. However, over time, the criteria for both deceased and living donors expanded significantly. Improved surgical techniques, better understanding of immunological compatibility, and enhanced screening protocols enabled the inclusion of older donors, donors with controlled hypertension, and even donors with certain transmissible infections under carefully managed conditions [3]. The introduction of paired kidney exchanges and advanced matching algorithms further optimized donor-recipient compatibility, thereby increasing the pool of available organs and

improving transplantation outcomes. These developments addressed the growing demand for donor kidneys, reducing wait times for recipients and expanding access to transplantation for a broader population.

The evolution of immunosuppressive therapy was another critical factor in the advancement of kidney transplantation [4]. Early transplantation efforts were plagued by high rates of graft rejection due to inadequate immunosuppressive regimens. The introduction of calcineurin inhibitors in the 1980s marked a significant turning point, substantially reducing acute rejection rates and improving short-term graft survival. Subsequently, the development of newer immunosuppressive agents, such as mycophenolate mofetil, mammalian target of rapamycin (mTOR) inhibitors, and monoclonal antibodies, offered more tailored and effective approaches to prevent rejection while minimizing the adverse effects associated with long-term immunosuppression [5]. These drugs enabled the fine-tuning of immunosuppressive protocols to individual patient needs, balancing the risks of rejection with the potential for drug toxicity and infection. Moreover, advancements in therapeutic drug monitoring and personalized medicine approaches allowed for more precise dosing and management of immunosuppressive therapy, further contributing to improved patient outcomes [6].

The long-term outcomes for kidney transplant recipients also saw remarkable improvements due to the aforementioned advancements in donor selection and immunosuppression. In earlier decades, chronic allograft nephropathy and the side effects of immunosuppressive drugs significantly limited graft survival and recipient longevity. However, with better donor matching, more effective immunosuppression, and improved posttransplant care, the incidence of chronic rejection decreased, and the overall survival of kidney grafts increased [7]. Additionally, advancements in managing comorbid conditions, such as

cardiovascular disease and infections, contributed to the long-term health and well-being of transplant recipients. The focus also shifted towards improving quality of life post-transplant, with increasing attention given to minimizing the impact of immunosuppression on metabolic health, bone density, and malignancy risk.

The advancements in kidney transplantation, particularly in donor selection, immunosuppression, and long-term outcomes, revolutionized the field and transformed the lives of countless individuals with ESRD [8]. The progress achieved over the years laid a strong foundation for continued innovation, with ongoing research and technological developments promising to further enhance the success and

accessibility of kidney transplantation in the future [9].

Materials and Methods:

Study Design and Duration

This study was designed as a retrospective and prospective cohort study to investigate the advancements in kidney transplantation, with a focus on donor selection, immunosuppression protocols, and long-term outcomes for recipients. The study was conducted over a 12-month period, from June 2023 to May 2024, and included both historical data and new data collected during the study period.

Study Population

The study population consisted of 90 kidney transplant recipients who underwent transplantation between January 2015 and December 2023. The inclusion criteria were patients aged 18 years or older who had received a kidney transplant during this period. The exclusion criteria included patients who had undergone multi-organ transplantation or those who had significant comorbidities that could confound the outcomes, such as active malignancy or severe cardiovascular disease at the time of transplantation.

Data Collection

Data were collected retrospectively from medical records for transplants performed between January 2015 and May 2023. For transplants performed

from June 2023 to May 2024, data were collected prospectively. Key variables included donor characteristics (e.g., age, gender, living or deceased status, HLA matching), recipient characteristics (e.g., age, gender, comorbidities, previous transplantation history), immunosuppression regimens, and long-term outcomes such as graft survival, patient survival, and incidence of rejection episodes.

Donor Selection

The study examined advancements in donor selection, particularly the criteria used to assess donor suitability. This included an evaluation of expanded criteria donors (ECD), the use of living donors, and the impact of HLA matching and donor-specific antibodies (DSA) on transplant outcomes. Data on donor kidney quality were collected, including the Kidney Donor Profile Index (KDPI) and any use of machine perfusion technologies.

Immunosuppression Protocols

The study assessed the evolution of immunosuppression protocols over the study period, focusing on the use of newer agents such as belatacept, mTOR inhibitors, and more precise dosing of calcineurin inhibitors. The impact of these protocols on short-term and long-term graft outcomes, as well as the incidence of adverse effects such as infections and malignancies, was analyzed. Specific attention was paid to the individualized approach in immunosuppressive

therapy based on recipient risk factors and the presence of DSA.

Long-Term Outcomes

Long-term outcomes were evaluated with a minimum follow-up of six months for patients who received transplants during the study period. Outcomes of interest included graft survival, patient survival, renal function (measured by serum creatinine and estimated glomerular filtration rate), and the occurrence of chronic allograft nephropathy. The study also assessed the incidence of complications such as infections, malignancies, and cardiovascular events, which are commonly associated with long-term immunosuppression.

Statistical Analysis

Descriptive statistics were used to summarize baseline characteristics of the study population. Kaplan-Meier survival analysis was employed to estimate graft and patient survival rates, and Cox proportional hazards models were used to identify risk factors for adverse outcomes. Logistic regression analysis was performed to evaluate the association between donor and recipient characteristics and the incidence of acute rejection episodes. Statistical significance was set at $p < 0.05$, and all analyses were conducted using SPSS version 27.0. **Ethical Considerations**

The study was approved by the institutional review board (IRB) of the participating hospital. Informed

consent was obtained from all prospective participants, and data from retrospective cases influencing kidney transplantation outcomes, with the goal of informing clinical practice and

Table 2: Immunosuppression Regimens and Graft Survival:

Regimen	Patients (n = 150)	Graft Survival at 1 Year (%)	Graft Survival at 5 Years (%)
Calcineurin Inhibitors (CNI) + Steroids	70	94%	85%
mTOR Inhibitors + Low-Dose CNI	50	90%	82%
Costimulation Blockade + Steroids	30	96%	88%

RESULTS:

Table 1: Donor Selection Criteria and Outcomes:

Criteria	Donors Selected (n = 150)	Successful Transplants (%)	Recipient Survival at 1 Year (%)
Standard Criteria Donors	80	92%	96%
Extended Criteria Donors	50	78%	85%
Living Donors	20	99%	98%

were anonymized to protect patient confidentiality. The study adhered to the Declaration of Helsinki guidelines and followed all relevant ethical standards in the conduct of research involving human subjects. This methodology aimed to provide a comprehensive assessment of the factors

improving patient care. In Table 1, donor selection was categorized into three groups: standard criteria donors, extended criteria donors, and living donors. Out of 150 transplants, 80 were from standard criteria donors, 50 from extended criteria donors, and 20 from living donors. The successful transplant rate was

highest for living donors at 99%, followed by 92% steroids. The highest graft survival rate at one year

Outcome	Standard Criteria Donors (n = 80)	Extended Criteria Donors (n = 50)	Living Donors (n = 20)
Graft Function at 5 Years (%)	88%	74%	95%
Chronic Rejection Rate (%)	12%	26%	5%
Patient Quality of Life Score	7.8	6.5	8.4

for standard criteria donors and 78% for extended criteria donors. The recipient survival rate at one year was also highest for living donors (98%), followed by standard criteria donors (96%) and extended criteria donors (85%). These findings illustrated the superior outcomes associated with living donors and emphasized the challenges of using extended criteria donors, who often have more comorbidities or are older, impacting the success and survival rates.

Table 2 presented data on the efficacy of different immunosuppression regimens in maintaining graft survival. The three regimens analysed included Calcineurin Inhibitors (CNI) combined with steroids, mTOR inhibitors combined with low-dose CNI, and Stimulation Blockade combined with

In Table 3, the long-term outcomes for recipients were assessed based on graft function at five years, chronic rejection rates, and patient quality of life. The study found that recipients of kidneys from

was observed with Costimulation Blockade combined with steroids at 96%, followed closely by CNI + Steroids at 94%. However, at five years,

Table 3: Long-Term Outcomes for Recipients:

the survival rates slightly declined across all groups, with the CNI + Steroids group showing an 85% survival rate, mTOR Inhibitors + Low-Dose CNI at 82%, and Costimulation Blockade + Steroids at 88%. These results underscored the effectiveness of Costimulation Blockade in preserving graft function over time, which might be attributed to its novel mechanism of preventing immune responses.

living donors had the best long-term outcomes, with 95% of grafts functioning well at five years, a low chronic rejection rate of 5%, and a high quality of life score of 8.4. In contrast, recipients of extended criteria donor kidneys exhibited lower

graft function (74%) and a higher chronic rejection rate (26%). Recipients of standard criteria donor kidneys had intermediate outcomes, with 88% graft function and a 12% chronic rejection rate.

The study highlighted that while extended criteria donors allowed for an increase in the donor pool, the associated risks were evident in the long-term outcomes. On the other hand, living donors continued to provide the best outcomes, emphasizing the need for strategies that could improve the outcomes associated with extended criteria donors. The study also confirmed that advancements in immunosuppressive therapies, particularly the use of Costimulation Blockade, had a positive impact on graft survival, although longterm studies were needed to confirm these benefits.

DISCUSSION:

Over the past few decades, significant advancements in kidney transplantation have reshaped the landscape of organ transplantation, leading to improved patient outcomes. These advancements encompassed a broad range of areas, including donor selection, immunosuppression strategies, and the long-term outcomes for recipients. Each of these areas played a crucial role in enhancing the success rates of kidney transplantation, making it a viable and often preferred treatment option for end-stage renal disease [10].

Donor Selection

In the past, the selection of kidney donors primarily relied on basic matching of blood type and tissue compatibility. However, advancements in genetic and immunological testing techniques significantly improved the donor selection process [11]. Techniques such as human leukocyte antigen (HLA) typing and crossmatching allowed for a more precise identification of compatible donors, which reduced the risk of organ rejection. Additionally, the understanding of the importance of matching HLA loci, particularly HLA-DR, evolved over time, enabling better matching between donors and recipients.

Moreover, the use of expanded criteria donors (ECD), including older donors and those with certain comorbidities, became more common [12]. Despite the increased risk of complications associated with ECD, these donors expanded the donor pool, addressing the issue of organ shortages. Advances in donor management, such as optimizing donor health before organ retrieval and improving organ preservation techniques, also played a vital role in enhancing the quality of organs available for transplantation.

Immunosuppression

The field of immunosuppression witnessed remarkable progress over the years, evolving from the use of high-dose steroids and azathioprine to the introduction of more targeted and less toxic agents [13]. Calcineurin inhibitors, such as cyclosporine

and tacrolimus, revolutionized the management of kidney transplant recipients by significantly reducing acute rejection rates. The development of mycophenolate mofetil and the adoption of mTOR inhibitors, such as sirolimus, further refined immunosuppressive regimens, offering a balance between preventing rejection and minimizing long-term side effects [14].

The past advancements in understanding the mechanisms of immune tolerance and the identification of biomarkers for immune monitoring also contributed to individualized immunosuppressive therapy. Tailoring immunosuppressive regimens to the specific needs of each patient reduced the risk of overimmunosuppression, which could lead to infections and malignancies, and underimmunosuppression, which increased the risk of rejection [15]. **Long-Term Outcomes**

The long-term outcomes of kidney transplantation improved markedly with these advancements. In earlier decades, patient and graft survival rates were limited due to high rates of acute rejection and the toxic effects of immunosuppressive drugs. However, with better donor selection and more effective immunosuppressive therapies, both short-term and long-term graft survival improved significantly [16].

The introduction of protocols for the early detection and treatment of chronic allograft nephropathy, which was a leading cause of graft loss, also played

a key role in extending graft survival. Additionally, the management of comorbid conditions, such as hypertension, diabetes, and infections, improved, contributing to better overall health and longevity of transplant recipients.

Moreover, the focus on long-term care, including regular monitoring for complications, adherence to immunosuppressive therapy, and lifestyle modifications, emerged as a critical component of post-transplant care [17]. The implementation of multidisciplinary teams, including nephrologists, transplant surgeons, and other specialists, ensured comprehensive care for recipients, addressing both the medical and psychosocial aspects of transplantation.

The advancements in kidney transplantation, particularly in donor selection, immunosuppression, and long-term outcomes, represented a significant leap forward in the field. These developments not only improved the survival and quality of life for kidney transplant recipients but also set the stage for future innovations, aiming for even better outcomes and broader access to this life-saving treatment [18].

CONCLUSION:

The advancements in kidney transplantation have significantly improved patient outcomes. Enhanced donor selection processes allowed for more precise matching, reducing the risk of rejection and improving graft survival. Innovations

in immunosuppression protocols minimized adverse effects while maintaining efficacy, leading to fewer complications and longer graft viability. As a result, long-term outcomes for recipients showed marked improvement, with extended survival rates and enhanced quality of life. These advancements collectively represented a major leap forward in the field, underscoring the importance of continued research and innovation to further refine and optimize kidney transplantation practices.

REFERENCES:

1. Szumilas K, Wilk A, Wiśniewski P, Gimpel A, Dziedziczko V, Kipp M, Pawlik A. Current status regarding immunosuppressive treatment in patients after renal transplantation. *International Journal of Molecular Sciences*. 2023 Jun 18;24(12):10301.
2. Pérez-Sáez MJ, Montero N, Oliveras L, Redondo-Pachón D, Martínez-Simón D, Abramovicz D, Maggiore U, Mariat C, Mjoen G, Oniscu GC, Peruzzi L. Immunosuppression of HLA identical living-donor kidney transplant recipients: A systematic review. *Transplantation Reviews*. 2023 Aug 1:100787.
3. Badrouchi S, Bacha MM, Ahmed A, Ben Abdallah T, Abderrahim E. Predicting long-term outcomes of kidney transplantation in the era of artificial intelligence. *Scientific Reports*. 2023 Dec 2;13(1):21273.
4. Purnomo AF, Nurkolis F, Syahputra RA, Moon S, Lee D, Taslim NA, Park MN, Daryanto B, Seputra KP, Satyagraha P, Lutfiana NC. Elucidating the nexus between onco-immunology and kidney transplantation: An insight from precision medicine perspective. *Heliyon*. 2024 Jul 15;10(13).
5. Han HS, Lubetzky ML. Immune monitoring of allograft status in kidney transplant recipients. *Frontiers in Nephrology*. 2023 Nov 8;3:1293907.
6. Rudzki G, Knop-Chodyła K, Piasecka Z, Kochanowska-Mazurek A, Głaz A, Wesolek-Bielaska E, Woźniak M. Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment. *Pharmaceuticals*. 2024 Jul 26;17(8):987.
7. Ramalhte L, Almeida P, Ferreira R, Abade O, Teixeira C, Araújo R. Revolutionizing Kidney Transplantation: Connecting Machine Learning and Artificial Intelligence with Next-Generation Healthcare—From Algorithms to Allografts. *BioMedInformatics*. 2024 Mar 1;4(1):673-89.
8. Adams AB, Blumberg EA, Gill JS, Katz E, Kawai T, Schold JD, Sykes M, Tector A, Sachs DH. Enhancing Kidney Transplantation and the Role of Xenografts: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. *American Journal of Kidney Diseases*. 2024 Jul 1;84(1):94-101.
9. Betjes MG, De Weerd A. Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots. *Frontiers in Medicine*. 2023 Jul 12;10:1215167.
10. Ali H, Mohammed M, Molnar MZ, Fülöp T, Burke B, Shroff S, Shroff A, Briggs D, Krishnan N. Live-donor kidney transplant outcome prediction (L-TOP) using artificial intelligence. *Nephrology Dialysis Transplantation*. 2024 Apr 29:gfae088.
11. Alotaibi M, Trollinger B, Kant S. Management of kidney transplant recipients for primary care practitioners. *BMC nephrology*. 2024 Mar 18;25(1):102.
12. Budhiraja P, Nguyen M, Heilman R, Kaplan B. The role of allograft

- nephrectomy in the failing kidney transplant. *Transplantation*. 2023 Dec 1;107(12):2486-96.
13. Chancharoenthana W, Traitanon O, Leelahavanichkul A, Tasanarong A. Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review. *Frontiers in Immunology*. 2023 Aug 22;14:1206929.
 14. Chancharoenthana W, Traitanon O, Leelahavanichkul A, Tasanarong A. Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review. *Frontiers in Immunology*. 2023 Aug 22;14:1206929.
 15. Kitchens WH, Larsen CP, Badell IR. Costimulatory Blockade and Solid Organ Transplantation: the Past, Present and Future. *Kidney International Reports*. 2023 Sep 3.
 16. Patrick G, Hickner B, Goli K, Ferreira LD, Goss J, Rana A. Trends in Survival for Adult Organ Transplantation. *Annals of Surgery Open*. 2024 Mar 1;5(1):e383.
 17. Paraskeva MA, Snell GI. Advances in lung transplantation: 60 years on. *Respirology*. 2024 Jun;29(6):458-70.
 18. Kajdas AA, Szostak-Węgierek D, Dąbrowska-Bender M, Normann AK, Søndergaard Linde D. Immunosuppressive therapy and nutritional status of patients after kidney transplantation: a protocol for a systematic review. *Journal of Clinical Medicine*. 2023 Nov 6;12(21):6955.
